| 摘要 |
Disclosed are synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) or a pharmaceutically acceptable salt or ester thereof and a topoisomerase I inhibitor, in particular irinotecan, and the use of the combination in the treatment of cancer and pharmaceutical compositions containing said combinations. Also disclosed are synergestic combinations of DMXAA or a pharmaceutically acceptable salt or ester thereof and doxorubicin, wherein the combination does not include an antibody, and the use of the combination in the treatment of cancer and pharmaceutical compositions containing said combinations.
|
